Fred joined LogicBio as CEO in April 2016 and previously held positions at companies including Shire, Pervasis Therapeutics and Genzyme. Based in Cambridge, MA (USA), LogicBio is working on new gene therapy / gene editing approaches to treat rare metabolic disorders in children. While the underlying “GeneRide” technology originally came out of Stanford University, LogicBio also has scientists in Tel Aviv, Israel.
